Aarti Drugs

₹449.90As of Sun 8 Nov 2026, 12:00 UTC

NSE:AARTIDRUGSHealthcare

Country India

PE (Fwd) 19.59

TSR 10Y CAGR 10.55%

Div yield 0.44%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.31

PE TTM 21.07

TSR TTM (7.90%)

Mkt cap ₹45.96B

ROIC —

SE Grade™

Value

Quality

Moat

—

1Y Price

Reference

₹497

10.38%

(56.33%)

Price above Reference Value

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

25.65

Revenue₹B

—

24.89

27.16

25.29

23.87

25.65

26.75

0.76%

7.47

Revenue growth%

—

9.14

(6.90)

(5.60)

7.47

4.29

0.94

—

35.95

Gross margin%

—

31.60

29.67

32.89

34.77

35.95

35.89

32.89

9.44

Operating margin%

—

11.59

9.40

10.48

9.69

9.44

9.37

9.69

7.60

Net margin%

—

8.24

6.12

6.78

7.04

7.60

7.53

7.04

21.07

P/E ratio (avg)x

—

29.24

21.48

27.51

26.64

21.04

20.38

26.64

16.95

EV/EBITx

—

20.79

13.99

17.79

19.37

16.93

16.37

17.79

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

21.36

EPS₹

—

22.14

17.96

18.65

18.42

21.36

22.08

(0.90%)

—

15.91

EPS growth%

—

(18.89)

3.82

(1.19)

15.91

3.38

1.32

—

Bookvalue per sh₹

—

FCF per share₹

—

2.00

Dividend per sh₹

—

1.00

2.00

2.19

18.92%

—

0.44

Div yield (avg)%

—

0.15

0.26

0.19

0.20

0.45

0.49

0.20

9.36

Payout ratio%

—

4.52

5.57

5.36

5.45

9.36

9.90

5.45

91.27

Shares (diluted)M

—

92.60

91.94

91.27

◌91.27

(0.36%)

—

Buyback yield%

—

0.72

—

◌—

0.36

—

D/E ratiox

—

41.06

Enterprise value₹B

—

59.96

35.72

47.15

44.80

41.01

41.06

(9.06%)

—

LT debt₹M

—

Peers (US$433.3M)

Cap (US$)

Evonile Pharma Limited

463.4M

—

Gufic Biosciences…

459.3M

58.86x

RPG Life Sciences…

450.8M

38.23x

Dong-A Pharmaceutical…

431.7M

7.863x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

7.185

7.668

Own earn%

—

Sh yield%

0.44

0.68

Owners

Insiders/Inst%

47.31

17.97

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

2/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

9–12

$1 testx

—

Incr. ROIC%

—

Aarti Drugs Limited, through its subsidiaries, engages in the manufacture and marketing of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹25.65B

0.76%

1.00×

Cost of revenue

₹16.43B

(0.88%)

0.94×

Operating expenses

₹6.800B

8.09%

1.32×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m